Business Context and Reporting Period
This Form 8-K reports on the 2018 Annual Meeting of Stockholders held by Aquinox Pharmaceuticals, Inc. on May 7, 2018. The meeting took place at the offices of Cooley LLP in Seattle, Washington. Note: The request metadata references "Neurogene Inc.," but the filing text explicitly identifies the registrant as Aquinox Pharmaceuticals, Inc.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
Stockholders voted on two proposals. The certified voting results are as follows:
Proposal 1: Election of Class I Directors
- David Main: 20,120,399 votes For; 117,266 votes Withheld; 1,352,372 Broker Non-Votes.
- Sean Nolan: 20,048,198 votes For; 189,467 votes Withheld; 1,352,372 Broker Non-Votes.
Both nominees were elected to serve until the 2021 Annual Meeting.
Proposal 2: Ratification of Independent Auditor
- Deloitte LLP: 21,373,514 votes For; 132,990 votes Against; 83,533 Abstentions.
Stockholders ratified the selection of Deloitte LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2018.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, management outlook, specific risks, contingencies, or unusual items. The document is limited to the submission of matters to a vote of security holders.
Key Facts for Investor Verification
- Confirm the registrant name is Aquinox Pharmaceuticals, Inc., not Neurogene Inc.
- Verify the successful election of directors David Main and Sean Nolan.
- Confirm the ratification of Deloitte LLP as the auditor for the 2018 fiscal year.
- Note the presence of significant broker non-votes (1,352,372) on the director election proposals.